New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
10th May 2023
Switzerland: The Federal Office of Public Health has given its approval to the cities of Bern, Lucerne and Biel to sell recreational cannabis in pharmacies as a pilot project. The project, involving over 1,000 participants, is expected to start in Bern in the autumn and in Lucerne and Biel at the beginning of 2024.
4th April 2023
Switzerland: The Federal Department of Home Affairs (FDHA) has amended the Ordinance on Narcotics and Psychotropic Substances to add hexahydrocannabinol (HHC) and ten other substances to the list of illegal new psychoactive substances. The list is already in force.
4th April 2023
Switzerland: The Federal Office of Public Health (FOPH) has given its approval to the city of Lausanne to sell recreational cannabis as a pilot project. The first harvest is scheduled for summer 2023 and points of sale should open around September. Lausanne is the third Swiss city to receive such approval, after Zurich and Basel.
23rd March 2023
Switzerland: The Federal Office of Public Health (FOPH) has granted the city of Zurich permission to launch a three-and-a-half-year pilot project to collect data on the regulated purchase of recreational cannabis and its effects on the health and consumption behaviour of users. Sales will be made through pharmacies, social clubs and drug information centres and are expected to start in August. Nine cannabis products will be offered, varying in THC and CBD content.
30th January 2023
27th January 2023
9th December 2022
2nd December 2022
5th October 2022
Switzerland: A pilot project to sell recreational cannabis in Zurich, previously planned for this autumn, has been postponed to the first half of 2023. According to the canton government, final approval has not yet been given by the Federal Office of Public Health and the delay is due, among other things, to the complexity of the project.
9th September 2022
18th August 2022
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.